Century Therapeutics (IPSC) Accumulated Depreciation (2020 - 2026)

Century Therapeutics (IPSC) has 7 years of Accumulated Depreciation data on file, last reported at $51.6 million in Q1 2026.

• Accumulated Depreciation for Q1 2026 came in at $51.6 million, up 31.96% year-over-year; the trailing twelve-month figure through Mar 2026 was $51.6 million (up 31.96% YoY), and the FY2025 annual result was $48.6 million, up 34.78% from the prior year.
• Accumulated Depreciation grew to $51.6 million in Q1 2026 per IPSC's latest filing, from $48.6 million in the prior quarter.
• Over five years, Accumulated Depreciation peaked at $51.6 million in Q1 2026 and troughed at $6.5 million in Q1 2022.
• A 5-year average of $27.7 million and a median of $26.0 million in 2024 frame the typical range for Accumulated Depreciation.
• The sharpest annual moves came in 2022 and 2026: Accumulated Depreciation soared 156.24% in 2022, then jumped 31.96% in 2026.
• A 5-year view of Accumulated Depreciation shows it stood at $13.7 million in 2022, then soared by 67.25% to $22.8 million in 2023, then surged by 57.89% to $36.1 million in 2024, then surged by 34.78% to $48.6 million in 2025, then increased by 6.18% to $51.6 million in 2026.
• Business Quant data shows IPSC's Accumulated Depreciation at $51.6 million in Q1 2026, $48.6 million in Q4 2025, and $45.6 million in Q3 2025.